Ausun Pharm: Imatinib Mesylate Tablets Obtained Drug Registration Certificate
I'm PortAI, I can summarize articles.
Ausun Pharm's wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Imatinib Mesylate Tablets issued by the National Medical Products Administration. This drug is the world's first molecular targeted therapy for tumors, primarily used to treat chronic myeloid leukemia and malignant gastrointestinal stromal tumors. The active ingredient, Imatinib, is a tyrosine kinase inhibitor that can inhibit the proliferation of abnormal white blood cells
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments